Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0248-8663(99)80114-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study.
J Eur Acad Dermatol Venereol
January 2025
Pfizer Inc, Paris, France.
Background: ALLEGRO-LT is an ongoing, long-term, open-label, multicentre, phase 3 study of ritlecitinib in adults and adolescents with alopecia areata (AA).
Objectives: To evaluate ritlecitinib safety and efficacy through Month 24 in patients with AA and ≥25% scalp hair loss.
Methods: ALLEGRO-LT enrolled rollover patients who previously received study intervention in either ALLEGRO phase 2a or 2b/3 studies and de novo patients who had not received treatment in either study.
Hair Transplantation on the Baldness Region with Free Latissimus Dorsi Flap for Scalp Reconstruction: A Case Report.
Arch Plast Surg
January 2025
Department of Plastic and Reconstructive Surgery, Seoul National University Boramae Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Scalp reconstruction, particularly with complex defects and infection risks, often favors microvascular free flaps. However, this method can result in unavoidable alopecia and undesirable aesthetics. This report describes a novel case where hair transplantation via follicular unit extraction (FUE) was applied to a free myocutaneous flap.
View Article and Find Full Text PDFImprovement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report.
Cureus
December 2024
Department of Dermatology, Duke University Medical Center, Durham, USA.
Folliculitis decalvans (FD) is a chronic inflammatory alopecia characterized by painful, scarring lesions and recurrent flares, often complicated by secondary bacterial infections. Despite the use of topical and systemic anti-inflammatory or antimicrobial therapies, FD remains challenging to manage, with limited therapeutic advancements. We report a case of recalcitrant FD in a man in his 40s who experienced significant symptom improvement and hair regrowth following the initiation of tirzepatide for weight management.
View Article and Find Full Text PDFManagement of Canine Leishmaniasis and the Treatment Trends of Veterinarians in Aegean Region of Türkiye: A Questionnaire-based Survey.
Turkiye Parazitol Derg
January 2025
Ege University Faculty of Medicine, Department of Parasitology, İzmir, Türkiye.
Objective: Canine leishmaniasis (CanL) is an important veterinary and public health problem in Mediterranean countries. Although CanL and vector sandflies are widespread in the study area, there are no standardized diagnostic and treatment methods followed by private clinics. This study aimed to survey (i) the treatment, diagnosis, and control measures preferred by veterinarians, (ii) compare the differences in the first-step diagnostic tests applied, and (iii) identify differences in the guidance for CanL.
View Article and Find Full Text PDFExploring the Physicochemical Compatibility of Minoxidil in Combination with Different Active Pharmaceutical Ingredients in Ready-to-use Vehicles for Alopecia Treatment.
Curr Drug Deliv
January 2025
Fagron BV - Fascinatio Boulevard 350, 3065 - WB Rotterdam, The Netherlands.
Background: Alopecia is globally known as a distressing medical disorder that affects men and women, and current commercially available minoxidil solutions are formulated with irritant vehicles with frequent complaints of dermatologic adverse effects.
Objectives: This study aimed to investigate further the compatibility of ready-to-use vehicles for the preparation of tailored formulations for alopecia treatment, namely TrichoSol™ (a ready-to-use vehicle for personalized hair solutions) and TrichoFoam™ (a ready-to-use vehicle for personalized foam formulations), in combination with minoxidil and other active pharmaceutical ingredients (APIs), to establish adequate beyond-use dates (BUD) for the given formulations.
Methods: Products under evaluation were compounded using TrichoSol™ or TrichoFoam™, with direct incorporation of the APIs into these vehicles.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!